Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No HPO annotations are available for this condition.
Bohring-Opitz syndrome (BOS) is a rare condition characterized by distinctive facial features and posture, variable but usually severe intellectual disability, growth failure, and variable anomalies. Feeding difficulties have a significant impact on overall health in early childhood; feeding tends to improve with age. This section summarizes clinical data from numerous case reports and case series; see and references therein, , and Suggested Reading. Additional references are cited where appropriate. Craniofacial. Individuals with BOS have a characteristic facial appearance , although significant variability is observed.
Prior to the identification of the molecular cause of Bohring-Opitz syndrome (BOS), had proposed clinical diagnostic criteria for the condition. Ultimately, only five individuals used to develop these clinical diagnostic criteria were molecularly confirmed to have BOS. Therefore, the specificity of these diagnostic criteria is unclear.
Bohring-Opitz syndrome should be suspected in individuals with the following clinical features [, , , , ]. Craniofacial appearance
No approved treatments are currently available for myeloid hemopathy. The disease remains an area of unmet medical need.
Gene therapy approaches for myeloid hemopathy have been reported in the published literature.
Evaluations Following Initial Diagnosis To establish the spectrum of manifestations and medical needs in an individual diagnosed with Bohring-Opitz syndrome (BOS), the following evaluations are recommended if they have not already been completed. Table 3. Recommended Evaluations Following Initial Diagnosis of Bohring-Opitz Syndrome
The following are appropriate:
Renal ultrasound every three months from birth to age eight years to screen for the development of Wilms tumor
Frequent monitoring of growth and development with interventions as needed
Close management of feeding intolerance with a gastroenterology specialist
No clinical trials have been registered for myeloid hemopathy.
24 publications have been identified in PubMed for myeloid hemopathy. Research spans Case Report / Case Series (29%), Basic Science / Preclinical (29%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 | 29% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:01 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Source: GeneReviews — "Bohring-Opitz Syndrome"
Glabellar and eyelid nevus flammeus (simplex) that fades with age
Prominent globes
Cleft lip
Palatal anomalies: cleft palate, high arched palate, or prominent palatine ridges
Micrognathia and/or retrognathia
Growth and feeding
Source: GeneReviews — "Bohring-Opitz Syndrome"
Table 2.
Disorders to Consider in the Differential Diagnosis of Bohring-Opitz Syndrome (BOS)
Disorder | Gene(s) | MOI | Clinical Features of Differential Diagnosis Disorder
Overlapping w/BOS | Distinguishing from BOS
C syndrome (Opitz trigonocephaly syndrome)1(OMIM 211750) | CD96 | AD | • Severe DD/ID
Microcephaly
Trigonocephaly
Upslanting palpebral fissures
Retrognathia
Low-set ears
| Common in BOS, not in C syndrome:
Nevus flammeus (simplex) over glabella
BOS posture
Poor linear growth
Feeding difficulties
High myopia
Shashi-Pena syndrome (ASXL2 syndrome)2 | ASXL2 | AD | • DD
Source: GeneReviews — "Bohring-Opitz Syndrome"
System/Concern | Evaluation | Comment |
|---|---|---|
Growth | Weight, length/height, head circumference measurements plotted on standard growth chart | Goal: normal weight-for-length or body mass index; Expected final adult height: 2nd centile |
ENT/Mouth | Craniofacial evaluation if cleft lip/palate, micrognathia, or obstructive sleep apnea is present | If mainly due to tongue-based airway obstruction, severe obstructive sleep apnea may be treatable by adenoidectomy or mandibular distraction. Gastrointestinal |
Neurologic | Assessment for signs/symptoms of seizures | If present, consider neurology evaluation head MRI. Evaluation by developmental specialists incl speech, occupational, physical therapists |
Cardiovascular | Echocardiogram for cardiac anatomy | — |
Respiratory | Assessment for apnea/bradycardia (more common in younger individuals) | Consider sleep study if sleep apnea is a concern. |
Eyes | Ophthalmology evaluation | For high myopia retinal/optic nerve defects |
Genitourinary | Baseline renal ultrasound | To assess renal structure screen for Wilms tumor |
Musculoskeletal | Orthopedic evaluation if bony anomalies noted | Miscellaneous/ |
Other | Consultation w/clinical geneticist /or genetic counselor | Treatment of Manifestations Table 4. |
Treatment of Manifestations in Individuals with BOS Manifestation/Concern | Treatment | Considerations/Other |
Frequent infections /or aspiration pneumonia4 | Aggressive management of chronic emesis | Fever or increase in emesis |
Seizures | Standard antiepileptic medications | Most individuals respond to monotherapy. |
Congenital heart defects | Standard management | Respiratory symptoms |
Sleep disturbances | Melatonin, treatment of anemia | — |
Myopia | Corrective lenses, often first prescribed in infancy | — |
Urinary retention, urinary tract infections, kidney stones | Standard treatments | Appropriate management of these conditions can improve emesis hospitalization rate. |
Source: GeneReviews — "Bohring-Opitz Syndrome"
View trials for myeloid hemopathy
Regular follow up with an ophthalmologist for vision optimization
Source: GeneReviews — "Bohring-Opitz Syndrome"
7 |
29% |
Disease patterns and progression | 4 | 17% |
Research summaries | 3 | 13% |
Clinical study results | 2 | 8% |
New treatment approaches | 1 | 4% |
Sirvent A (2026). [PMID: 40998674](https://pubmed.ncbi.nlm.nih.gov/40998674/). *Bull Cancer*. [Review / Meta-Analysis]
da Silva-Benedito S (2026). [PMID: 41939253](https://pubmed.ncbi.nlm.nih.gov/41939253/). *Hemasphere*. [Review / Meta-Analysis]
Benallaoua K (2026). [PMID: 41918936](https://pubmed.ncbi.nlm.nih.gov/41918936/). *SAGE Open Med Case Rep*. [Case Report / Case Series]
Cayuela JM (2025). [PMID: 40908230](https://pubmed.ncbi.nlm.nih.gov/40908230/). *Bulletin du cancer*. [Basic Science / Preclinical]
Trněný M (2025). [PMID: 40088467](https://pubmed.ncbi.nlm.nih.gov/40088467/). *Blood advances*. [Review / Meta-Analysis]
Mosnier C (2025). [PMID: 39820709](https://pubmed.ncbi.nlm.nih.gov/39820709/). *Blood advances*. [Basic Science / Preclinical]
Vener C (2025). [PMID: 40056559](https://pubmed.ncbi.nlm.nih.gov/40056559/). *European journal of cancer (Oxford, England : 1990)*. [Gene Therapy / Novel Therapeutics]
Le Grand S (2025). [PMID: 39949376](https://pubmed.ncbi.nlm.nih.gov/39949376/). *HemaSphere*. [Epidemiology / Natural History]
Stefanes NM (2025). [PMID: 39186189](https://pubmed.ncbi.nlm.nih.gov/39186189/). *Naunyn-Schmiedeberg's archives of pharmacology*. [Case Report / Case Series]
Ssenyonga N (2025). [PMID: 40578047](https://pubmed.ncbi.nlm.nih.gov/40578047/). *European journal of cancer (Oxford, England : 1990)*. [Epidemiology / Natural History]